Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02555150 · ClinicalTrials.gov registry record · Phase 3
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
A Phase 3 study, sponsored by Rhodes Pharmaceuticals, L.P..
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT02555150 is a Phase 3 study that has completed, run by Rhodes Pharmaceuticals, L.P.. The registered enrollment target is 40 participants.
The verdict
NCT02555150, a Phase 3 study, has completed, sponsored by Rhodes Pharmaceuticals, L.P..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this randomized, double-blind, crossover study is to compare two long-acting stimulant formulations-once-daily PRC-063 and once-daily lisdexamfetamine (LDX)-through a 15-hour period on driving performance, as measured with a driving simulator, in adult patients with ADHD.
Interventions
- DRUG Placebo
- DRUG lisdexamfetamine dimesylate
- DRUG PRC-063
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02555150
The ClinicalTrials.gov registry entry for NCT02555150 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhodes Pharmaceuticals, L.P., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02555150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02555150 about?
NCT02555150 is a clinical study titled "A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD". The purpose of this randomized, double-blind, crossover study is to compare two long-acting stimulant formulations-once-daily PRC-063 and once-daily lisdexamfetamine (LDX)-through a 15-hour period on driving performance, as measured with a driving simulator, in adult patients with ADHD.
What is the current status of trial NCT02555150?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2015-09. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02555150?
The interventions under investigation include: Placebo (DRUG), lisdexamfetamine dimesylate (DRUG), PRC-063 (DRUG).
Who is sponsoring clinical trial NCT02555150?
This trial is sponsored by Rhodes Pharmaceuticals, L.P., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.